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What is already known about the topic?
•• People with head and neck cancer have unique and complex needs due to the impact from both the disease and its 
treatment.
•• Early engagement of Specialist Palliative Care has been shown to have a beneficial impact on cancer patients and family 
carers, but the best way to integrate this care for those with head and neck cancer needs further clarification.
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Abstract
Background: Few large studies describe initial disease trajectories and subsequent mortality in people with head and neck cancer. 
This is a necessary first step to identify the need for palliative care and associated services.
Aim: To analyse data from the Head and Neck 5000 study to present mortality, place and mode of death within 12 months of diagnosis.
Design: Prospective cohort study.
Participants: In total, 5402 people with a new diagnosis of head and neck cancer were recruited from 76 cancer centres in the United 
Kingdom between April 2011 and December 2014.
Results: Initially, 161/5402 (3%) and 5241/5402 (97%) of participants were treated with ‘non-curative’ and ‘curative’ intent, 
respectively. Within 12 months, 109/161 (68%) in the ‘non-curative’ group died compared with 482/5241 (9%) in the ‘curative’ group. 
Catastrophic bleed was the terminal event for 10.4% and 9.8% of people in ‘non-curative’ and ‘curative’ groups, respectively; terminal 
airway obstruction was recorded for 7.5% and 6.3% of people in the same corresponding groups. Similar proportions of people in both 
groups died in a hospice (22.9% ‘non-curative’; 23.5% ‘curative’) and 45.7% of the ‘curative’ group died in hospital.
Conclusion: In addition to those with incurable head and neck cancer, there is a small but significant ‘curative’ subgroup of people 
who may have palliative needs shortly following diagnosis. Given the high mortality, risk of acute catastrophic event and frequent 
hospital death, clarifying the level and timing of palliative care services engagement would help provide assurance as to whether 
palliative care needs are being met.
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What this paper adds?
•• Two-thirds of people with head and neck cancer treated with ‘non-curative’ intent and almost 10% of those treated with 
‘curative intent’ died within the 12 months following initial diagnosis.
•• Over a fifth of people with head and neck cancer, irrespective of their original treatment intent, died in a hospice which 
is greater than the proportion of those with cancer as a whole.
•• Between 6% and 11% died from acute bleeding or airway obstruction.
Implications for practice, theory or policy
•• Further understanding about current levels and timing of palliative care service engagement would be a useful next step 
in determining to what degree palliative care needs for those with head and neck cancer are met.
•• Identifying people with ‘high risk’ head and neck cancer at the point of diagnosis and exploring their care needs in 
greater detail also represent an area of further study.
Background
Evidence to support the benefits of early access to 
Specialist Palliative Care, often concurrent with active 
oncology care, has expanded rapidly over the last decade. 
Studies suggest that Specialist Palliative Care improves 
quality of life, symptom control and aspects of doctor–
patient communication.1–6 There are a number of unan-
swered questions, however, relating to the optimum 
service model and how to promote timely patient identi-
fication and referral.1 Previous studies have mainly 
focused on solid organ tumours such as lung and upper 
gastrointestinal cancer. Little attention has been paid to 
people with head and neck cancer despite the well-recog-
nised complexities of both the cancer and its treatment.7 
Fundamental changes can occur affecting individuals’ 
appearance8,9 and their ability to eat, speak and 
breathe.10–12 The subsequent psychological and social 
impact for both those with head and neck cancer and 
their family carers is significant.13
At presentation, about 60% of people with head and 
neck cancer have advanced disease (stage III or IV) and 
recurrence following treatment is high.14,15 The median 
overall survival for those with recurrent or metastatic dis-
ease is less than 1 year.16 Engagement with Specialist 
Palliative Care services can vary. One American study 
observed that individuals having a diagnosis of head and 
neck cancer was associated with early referral to 
‘Supportive and palliative care’ services.17 Another study 
involving those with terminal head and neck cancer 
(defined as having distal metastatic disease), however, 
suggested under-utilisation of in-patient palliative care 
consultations.18 In order to develop and direct targeted 
services to best support people with head and neck can-
cer, a greater understanding of the potential palliative 
care needs and challenges for this population is required.19 
There are few large-scale studies describing initial disease 
trajectories and subsequent mortality of people with 
head and neck cancer – a necessary first step in identify-
ing the potential need for palliative care.
We present results from the ‘Head and Neck 5000’ 
resource,20,21 a large clinical cohort study in people with 
head and neck cancer within the United Kingdom. We 
focus on disease trajectories; compare mortality for those 
treated with ‘non-curative’ and ‘curative’ intent; examine 
the place and mode of death for those who died within 
the first 12 months; and assess the subsequent mortality 
during the study period.
Methods
Study population
The study methods have previously been described.20 
Within 76 UK cancer centres, all people aged 16 years or 
over with a new diagnosis of head and neck cancer were 
eligible. People treated with curative intent were 
recruited before treatment started (unless part of a 
diagnostic procedure) and participants offered pallia-
tive support were recruited as soon after diagnosis as 
possible.22
Recruitment
Participants were recruited between 1 April 2011 and 31 
December 2014. Written informed consent, obtained by 
research nurses based in local centres, included consent 
for collection of clinical data from case records and record 
linkage.
Treatment intent
Baseline data capture forms completed by the research 
sites were used to define ‘cancer plan intent’,21 defined 
as the intention of treatment, as specified in the final 
pre-treatment multi-disciplinary team (MDT) meeting. 
The research teams at each site were subsequently 
(4 months later) asked to indicate which option best 
reflected the treatment received (rather than planned) 
and were defined as:
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•• Curative: underwent treatment that intends, how-
ever slight the chance of success, to cure.
•• Palliative anti-cancer: underwent treatments such 
as chemotherapy, radiotherapy or surgery but it is 
known that the cancer cannot be cured.
•• Supportive: refers to ‘best supportive care’ aimed 
at relieving symptoms but is not as intensive a 
treatment as ‘palliative anti-cancer’; it is known 
that the cancer cannot be cured.
•• No specific anti-cancer: patient declined to have 
any treatment.
Within this study, participants were categorised into 
two groups reflecting the treatment they received – those 
treated with ‘curative’ intent and those treated with ‘non-
curative intent’ (i.e. a combination of the other groups).
Baseline data collection
Health, lifestyle and socio-demographic measure-
ments. Socio-demographic, health and lifestyle meas-
ures including age at consent, gender, smoking status, 
alcohol consumption and World Health Organization 
(WHO) performance status were collected using self-
report questionnaires.20 Smoking status was categorised 
as never, current or former smoker. Alcohol consumption 
was categorised as non-drinker, moderate drinker 
(˂14 units per week for men and women), hazardous 
drinker (14–50 units/week for men and 14–35 units/week 
for women) and harmful drinker (>50 units/week for 
men and >35 units/week for women), where one unit of 
alcohol = 8 g/10 mL ethanol.23 WHO performance status 
ranged from zero (‘normal activity’) to four (‘confined to 
bed or chair more than 50 percent of the time’).24 We 
linked the English Index of Multiple Deprivation (IMD) 
2010 quintiles using participants’ home postcode – group 
1 represented the most deprived people and group 5 rep-
resented the least deprived people.25
Clinical measures. Anatomical site was recorded using 
the International Classification of Diseases (ICD) 10 
codes.26 Where possible, clinical data were checked 
against pathology forms. We grouped anatomical site 
into: lip and oral cavity squamous cell carcinoma (SCC) 
(C00, C02-C06), oropharynx SCC (C01, C05.1, 2, C09.0, 1, 
9, C10.0, 2, 3), larynx SCC (C32.0, 1, 2, C10.1), other SCC 
(C07-C08, C11-C14, C30-C31, C41.1, C69.5) and other 
non-SCC (and ICD code with non-SCC histology) tumours.
Other clinical data included clinical stage, co-morbidity 
status, treatment modality and human papillomavirus (HPV) 
status. Stage was grouped into four categories (I, II, III, IV) 
using the Tumour, Node and Metastasis version 7.27 
Comorbidity was measured using the Adult Comorbidity 
Evaluation28 – participants were grouped into four catego-
ries including no co-morbidity, mild co-morbidity, moderate 
decompensation and severe decompensation. Treatment 
was defined at 4 months based on the treatment received 
(rather than planned). Anti-cancer treatments were defined 
as single modality (subdivided into ‘surgery only’, ‘radiother-
apy only’ or ‘chemotherapy only’); chemoradiotherapy 
only; surgery combined with other anti-cancer treatment; 
and no anti-cancer treatment. HPV status was defined as a 
serological response to HPV 16 E6 protein using a glu-
tathione S-transferase multiplex assay undertaken at the 
German Cancer Research Center (DKFZ), Heidelberg, 
Germany. A cut-off value of more than 1000 median fluores-
cence intensity (MFI) units defined a positive response.29,30
Follow-up
Follow-up questionnaires were sent out 4 and 12 months 
after the participant was recruited and research nurses 
collected updated clinical information from hospital medi-
cal records concurrently. On 11 October 2018, the cohort 
was linked to the National Office of Statistics mortality 
data, which provided at least 3½ years of follow-up.
Statistical analysis
Demographic data are presented along with p-values to 
test for differences between ‘curative’ and ‘non-curative’ 
groups. Survival time was measured as the time from 
study consent until either death or the end of the most 
recent follow-up period. Cox proportional Hazards models 
were estimated with 95% confidence intervals (CIs) to 
determine differences in the predictors of all-cause mor-
tality for each variable included in the analysis (both 
unadjusted and adjusted for age and sex) and to compare 
between ‘curative’ versus ‘non-curative’ models. p-values 
were displayed to test for the trend across each group for 
ordinal variables, and individual p-values were displayed 
to test for the differences between hazard ratios (HRs) for 
unordered variables. Descriptive data from mortality 
forms were presented along with percentages and 95% CI 
for proportions. All statistical analyses were performed 
using Stata (Version 15.0).31,32
Ethical approval
The study was approved by the National Research Ethics 
Committee (South West Frenchay Ethics Committee, ref-
erence 10/H0107/57, 5 November 2010) and approved by 




From the 5511 participants who consented, 109 were 
excluded from analyses (Figure 1). From the remaining 
5402, 161 (3%) were treated with ‘non-curative’ intent 
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and 5241 (97%) treated with ‘curative’ intent. Comparison 
of baseline data between those treated with ‘non-cura-
tive’ and ‘curative’ intent showed those within the ‘non-
curative’ group were older, had a higher proportion of 
moderate or severe co-morbidities, poorer WHO perfor-
mance status and were twice as likely to present with 
Stage IV disease (Table 1). In addition, those within the 
‘non-curative’ group were more likely to have ‘other SCC’ 
as their primary tumour site, be HPV-negative, not 
undergo surgery but rather have single or no definitive 
anti-cancer treatment.
Mortality up to 12 months following 
diagnosis
Within the first 4 months, 39/161 (24%) of those treated 
with ‘non-curative’ intent had died compared with 
123/5241 (2.3%) of those in the ‘curative’ group. At 
12 months, 109/161 (67.7%) of those in the ‘non-curative’ 
group had died. From the initial ‘curative’ intent group, 
482/5241 (9%) had died and 162/5241 (3%) were now 
being treated with ‘non-curative’ intent (Figure 1). In 
total, 591/5402 (10.9%) had died within the initial 
12 months following diagnosis.
Overall survival results
Participants were followed up for at least 3½ years. During 
this time, most people treated at baseline with ‘non-cura-
tive’ intent died (n = 147/161, 91.3%) as did 30% of those 
treated curatively (n = 1573/5241).
People in the ‘non-curative’ group had markedly worse 
survival than those with stage IV tumours in the ‘curative’ 
group (Figure 2). Within the ‘non-curative’ group, those 
with a poorer WHO performance status were more likely 
to die within the total study period (Table 2). Within the 
‘curative’ group, those who were older, male, had severe 
co-morbidities, poor WHO performance status, a higher 
deprivation score, were currently smoking and with more 
advanced disease stage were more likely to die within the 
study period (Table 3). Those who were treated solely 
with chemotherapy had a markedly higher HR. There 
were only 14 people in this group, however, and nine 
were identified as ‘non-curative’ within 12 months.
People in the ‘non-curative’ group had a ninefold 
higher risk of death (unadjusted HR = 9.22 (95% CI, 7.8 to 
11.0)) compared with those in the ‘curative’ group 
(Supplementary Table 1). Following full adjustment, the 
HR attenuated but they still had almost a threefold higher 
risk of all-cause mortality than the patients in the ‘non-
curative’ group (HR = 2.95 (95% CI = 2.0 to 4.3).
Cause, mode and place of death
Mortality feedback forms were completed for 549/591 
(93%) participants who died within the first year of the 
study (Table 4). From those in the ‘non-curative’ group, 
5/48 (10.4%) people who had died within the first 
12 months had a catastrophic bleed and 3/40 (7.5%) had 
an airway obstruction as a terminal event. Similarly, 22/224 
(9.8%) and 12/192 (6.3%) from those in the ‘curative’ 
group had a bleed or airway obstruction, respectively.
Figure 1. Diagram displaying cohort recruitment and status of patients receiving curative or non-curative treatment at baseline, 
4 months and 12 months.
*Died between baseline and 4 months.
^Died between 4 and 12 months.
‘Unknown’ = patients are alive, but their treatment intent has not been recorded.
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Table 1. Comparison at baseline between ‘non-curative’ intent group and ‘curative’ intent group.
Non-curative intent Curative intent p-value for trend
Total 161 5241  
Mean age at consent (SD) 69.1 (11.6) 60.6 (11.7) <0.001
Age at consent group  
 Less than 54 13 (8.1%) 1501 (28.6%) <0.001
 55–64 46 (28.6%) 1754 (33.5%)  
 65 and older 102 (63.4%) 1986 (37.9%)  
 Total 161 5242  
Gender 0.850
 Male 116 (72.0%) 3812 (72.7%)  
 Female 45 (28.0%) 1429 (27.3%)  
 Total 161 5242  
Comorbidity  
 No comorbidity 27 (16.9%) 2268 (44.3%) <0.001
 Mild 47 (29.4%) 1734 (33.8%)  
 Moderate 50 (31.3%) 903 (17.6%)  
 Severe decompensation 36 (22.5%) 219 (4.3%)  
 Total 160 5125  
WHO performance status  
 Normal activity 19 (20.0%) 2131 (56.7%) <0.001
 Strenuous activity restricted 31 (32.6%) 962 (25.6%)  
 Up and about >50% 25 (26.3%) 504 (13.4%)  
 Confined to bed or chair >50% 20 (21.1%) 163 (4.3%)  
 Total 95 3759  
Smoking status  
 Current smoker 25 (25.8%) 722 (19.4%) 0.064
 Former smoker 57 (58.8%) 2081 (55.8%)  
 Never smoked 15 (15.5%) 926 (24.8%)  
 Total 97 3728  
Alcohol  
 Non-drinker 32 (33.0%) 1075 (28.3%) 0.410
 Moderate drinker 17 (17.5%) 856 (22.5%)  
 Hazardous/harmful drinker 48 (49.5%) 1873 (49.2%)  
 Total 97 3733  
IMD Quintilea  
 1 – Most deprived 39 (27.7%) 1006 (21.0%) 0.081
 2 34 (24.1%) 914 (19.1%)  
 3 22 (15.6%) 1056 (22.0%)  
 4 23 (16.3%) 903 (18.8%)  
 5 – Most affluent 23 (16.3%) 916 (19.1%)  
 Total 141 4794  
Tumour site  
 Oral cavity SCC 28 (17.7%) 1247 (23.9%) <0.001
 Oropharynx SCC 37 (23.4%) 1848 (35.4%)  
 Larynx SCC 22 (13.9%) 1019 (19.5%)  
 Other SCC 53 (33.5%) 575 (11.0%)  
 Non-SCC 18 (11.4%) 535 (10.2%)  
 Total 158 5225  
Tumour stage  
 I/II/III 22 (15.4%) 2766 (55.2%) <0.001
 IV 121 (84.6%) 2245 (44.8%)  
 Total 143 5009  
HPV-16 Status  
 Negative 118 (92.2%) 3154 (71.5%) <0.001
 Positive 10 (7.8%) 1257 (28.5%)  
(Continued)
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From those who had died within the first 12 months 
and had a completed mortality form, there was a sugges-
tion that more of those in the ‘curative’ group died in hos-
pital compared with the ‘non-curative’ group (p = 0.09) 
(Table 4). Similar proportions of those within the ‘non-




The vast majority of people within this cohort were 
treated with curative intent. The small proportion treated 
with ‘non-curative’ intent had recognised risk factors that 
were associated with poor prognosis including increasing 
age, advanced stage of disease and multiple co-morbidi-
ties. Two-thirds of those initially treated with ‘non-cura-
tive’ intent and almost 10% of those treated curatively 
died within the first 12 months following initial head and 
Non-curative intent Curative intent p-value for trend
 Total 128 4418  
Treatment  
 Surgery only 3 (1.9%) 1311 (25.0%) <0.001
 Chemoradiotherapy only 21 (13.0%) 1563 (29.8%)  
 Radiotherapy only 81 (50.3%) 970 (18.5%)  
 Surgery and radio/chemo/chemoradio 4 (2.5%) 1359 (25.9%)  
 Chemotherapy only 21 (13.0%) 14 (0.3%)  
 No anti-cancer treatment 31 (19.3%) 24 (0.5%)  
 Total 161 5242  
WHO: World Health Organization; IMD: English Index of Multiple Deprivation; SCC: squamous cell carcinoma; HPV: human papillomavirus; SD: stan-
dard deviation.
aEnglish patients only.
Figure 2. Kaplan–Meier plot of survival up to 8 years after 
diagnosis comparing non-curative with curative treatment 
intent (curative intent stratified by stage).
Table 1. (Continued)
neck cancer diagnosis. The latter group potentially repre-
sents a cohort of people who after undergoing initial cura-
tive treatment were quickly identified to have residual or 
recurrent cancer, necessitating a change in treatment 
intent to a palliative approach.
During the study period, the risk of death was over 
nine times greater for those in the ‘non-curative’ group 
compared with the ‘curative’ group. From the participants 
who died within 12 months of diagnosis, over one-fifth of 
people with head and neck cancer, irrespective of their 
original treatment intent, died in a hospice.
What this study adds and implications for 
practice
When an individual is diagnosed with head and neck can-
cer, survival and treatments that offer the best chance of 
cure are usually the primary concern.33 Hence, it is unsur-
prising that most people in our study were treated with 
‘curative’ intent at the point of diagnosis. Knowledge 
about place of death helps our understanding regarding 
service needs and development. From those who died 
within the first 12 months, over a fifth of people with 
head and neck cancer, irrespective of their original treat-
ment intent, died in a hospice. This is greater than the 
observed numbers of head and neck cancer deaths in a 
‘hospice ward’ (14.6%) within a large Taiwanese study.34 
The observed proportion of hospice deaths is also greater 
than the 16% of people with all forms of cancer who died 
within a hospice in England between 1993 and 2010.35 In 
part, this may reflect the complexities of care, including 
the risk of acute catastrophic events and the need for spe-
cialist care. Within this cohort, between 6% and 11% had 
a catastrophic event as a terminal event, greater than the 
3%–5% previously reported to have ‘carotid blowout 
syndrome’.36
Different models of providing palliative care exist,37 
but the optimum model for those with head and neck 
cancer remains unclear. Compared with other cancers, 
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Table 2. Predictors of survival in people treated with non-curative intent at baseline.
Unadjusted model p-value Age- and sex-adjusted model p-value
Age at consent group (n = 161) 0.793*  
 Less than 54 1.00 (Ref.) – –
 55 to 64 0.75 (0.40, 1.40) – –
 65 and older 0.81 (0.45, 1.45) – –
Gender (n = 161) 0.843  
 Male 0.96 (0.67, 1.38) – –
 Female 1.00 (Ref.) – –
Comorbidity (n = 160) 0.484* 0.379*
 No comorbidity 1.00 (Ref.) 1.00 (Ref.)  
 Mild 1.21 (0.74, 2.00) 1.36 (0.78, 2.34)  
 Moderate 1.20 (0.74, 1.96) 1.33 (0.78, 2.25)  
 Severe decompensation 1.24 (0.73, 2.09) 1.35 (0.78, 2.34)  
WHO performance status (n = 95) 0.069* 0.016*
 Normal activity 1.00 (Ref.) 1.00 (Ref.)  
 Strenuous activity restricted 0.90 (0.49, 1.66) 0.84 (0.43, 1.62)  
 Up and about >50% 1.13 (0.61, 2.12) 1.16 (0.59, 2.29)  
 Confined to bed or chair >50% 1.77 (0.92, 3.39) 2.27 (1.14, 4.54)  
Smoking status (n = 97) 0.577* 0.817*
 Current smoker 0.90 (0.45, 1.80) 0.94 (0.45, 1.95)  
 Former smoker 1.29 (0.70, 2.37) 1.22 (0.66, 2.29)  
 Never smoked 1.00 (Ref.) 1.00 (Ref.)  
Alcohol consumption (n = 97) 0.461* 0.735*
 Non-drinker 1.00 (Ref.) 1.00 (Ref.)  
 Moderate drinker 0.63 (0.33, 1.21) 0.63 (0.33, 1.21)  
 Hazardous/harmful drinker 0.81 (0.50, 1.30) 0.90 (0.56, 1.47)  
IMD Quintile (n = 141) 0.706* 0.728*
 1 – Most deprived 1.00 (0.59, 1.72) 1.01 (0.59, 1.73)  
 2 0.81 (0.47, 1.39) 0.78 (0.45, 1.36)  
 3 0.60 (0.33, 1.12) 0.60 (0.32, 1.11)  
 4 0.76 (0.41, 1.40) 0.75 (0.40, 1.41)  
 5 – Most affluent 1.00 (Ref.) 1.00 (Ref.)  
Tumour site (n = 158)  
Oral cavity  SCC 1.00 (Ref.) 1.00 (Ref.)  
 Oropharynx SCC 0.82 (0.49, 1.37) 0.438 0.78 (0.45, 1.34) 0.359
 Larynx SCC 0.76 (0.42, 1.37) 0.364 0.76 (0.42, 1.36) 0.365
 Other SCC 0.82 (0.51, 1.31) 0.399 0.81 (0.50, 1.33) 0.411
 Non-SCC 0.61 (0.32, 1.16) 0.133 0.61 (0.32, 1.15) 0.125
Tumour stage (n = 143) 0.332 0.416
 I/II/III 1.00 (Ref.) 1.00 (Ref.)  
 IV 1.27 (0.78, 2.07) 1.23 (0.75, 2.03)  
HPV-16 Status (n = 123) 0.884 0.854
 Negative 1.00 (Ref.) 1.00 (Ref.)  
 Positive 1.05 (0.53, 2.08) 1.07 (0.51, 2.28)  
Treatment (n = 161)  
 Surgery only 1.00 (Ref.) 1.00 (Ref.)  
 Chemoradiotherapy only 0.98 (0.29, 3.31) 0.970 0.96 (0.27, 3.36) 0.945
 Radiotherapy only 1.07 (0.34, 3.40) 0.912 1.10 (0.34, 3.51) 0.873
  Surgery and radio/chemo/
chemoradio
0.47 (0.09, 2.32) 0.353 0.47 (0.09, 2.36) 0.361
 Chemotherapy only 0.86 (0.25, 2.92) 0.809 0.87 (0.25, 3.03) 0.831
 No anti-cancer treatment 1.97 (0.60, 6.51) 0.264 2.08 (0.62, 6.96) 0.236
WHO: World Health Organization; IMD: English Index of Multiple Deprivation; SCC: squamous cell carcinoma; HPV: human papillomavirus.
*p-value for trend.
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Table 3. Predictors of survival in people treated with curative intent at baseline.
Unadjusted model HR p-value Age- and sex-adjusted model HR p-value
Age at consent group (n = 5241) <0.001*  
 Less than 54 1.00 (Ref.) – –
 55 to 64 1.60 (1.38, 1.85) – –
 65 and older 2.35 (2.05, 2.69) – –
Gender (n = 5241) <0.001*  
 Male 1.46 (1.29, 1.65) – –
 Female 1.00 (Ref.) – –
Comorbidity (n = 5214) <0.001* <0.001*
 No comorbidity 1.00 (Ref.) 1.00 (Ref.)  
 Mild 1.66 (1.47, 1.88) 1.43 (1.27, 1.63)  
 Moderate 2.53 (2.21, 2.89) 2.11 (1.84, 2.43)  
 Severe decompensation 4.30 (3.56, 5.21) 3.51 (2.88, 4.27)  
WHO performance status (n = 3760) <0.001* <0.001*
 Normal activity 1.00 (Ref.) 1.00 (Ref.)  
 Strenuous activity restricted 1.88 (1.63, 2.18) 1.79 (1.55, 2.08)  
 Up and about >50% 2.46 (2.08, 2.91) 2.33 (1.97, 2.76)  
 Confined to bed or chair >50% 3.90 (3.11, 4.89) 3.60 (2.87, 4.51)  
Smoking status (n = 3729) <0.001* <0.001*
 Current smoker 2.84 (2.34, 3.43) 2.83 (2.34, 3.44)  
 Former smoker 1.73 (1.45, 2.06) 1.57 (1.32, 1.87)  
 Never smoked 1.00 (Ref.) 1.00 (Ref.)  
Alcohol consumption (n = 3804) 0.203* 0.404*
 Non-drinker 1.00 (Ref.) 1.00 (Ref.)  
 Moderate drinker 0.74 (0.61, 0.88) 0.71 (0.59, 0.86)  
 Hazardous/harmful drinker 1.05 (0.91, 1.21) 1.02 (0.88, 1.18)  
IMD Quintile (n = 4795) <0.001* <0.001*
 1 – Most deprived 1.43 (1.21, 1.68) 1.49 (1.27, 1.76)  
 2 1.25 (1.05, 1.48) 1.27 (1.08, 1.51)  
 3 1.16 (0.98, 1.38) 1.17 (0.99, 1.38)  
 4 0.98 (0.82, 1.18) 0.97 (0.81, 1.16)  
 5 – Most affluent 1.00 (Ref.) 1.00 (Ref.)  
Tumour site (n = 5224)  
Oral cavity  SCC 1.00 (Ref.) 1.00 (Ref.)  
 Oropharynx SCC 0.70 (0.62, 0.80) <0.001 0.73 (0.64, 0.83) <0.001
 Larynx SCC 0.81 (0.70, 0.93) 0.004 0.68 (0.58, 0.79) <0.001
 Other SCC 1.13 (0.96, 1.32) 0.146 1.13 (0.96, 1.32) 0.152
 Non-SCC 0.46 (0.37, 0.58) <0.001 0.57 (0.45, 0.71) <0.001
Tumour stage (n = 5011) <0.001 <0.001
 I/II/III 1.00 (Ref.) 1.00 (Ref.)  
 IV 1.74 (1.57, 1.93) 1.82 (1.64, 2.02)  
HPV-16 Status (n = 4411) <0.001 <0.001
 Negative 1.00 (Ref.) 1.00 (Ref.)  
 Positive 0.47 (0.41, 0.55) 0.50 (0.44, 0.58)  
Treatment (n = 5241)  
 Surgery only 1.00 (Ref.) 1.00 (Ref.)  
 Chemoradiotherapy only 1.58 (1.36, 1.84) <0.001 1.65 (1.41, 1.92) <0.001
 Radiotherapy only 2.02 (1.72, 2.37) <0.001 1.67 (1.41, 1.96) <0.001
 Surgery and radio/chemo/chemoradio 1.94 (1.66, 2.25) <0.001 1.94 (1.67, 2.26) <0.001
 Chemotherapy only 27.10 (15.49, 47.39) <0.001 26.47 (15.11, 46.37) <0.001
 No anti-cancer treatment 6.97 (4.20, 11.55) <0.001 6.84 (4.12, 11.34) <0.001
HR: hazard ratio; WHO: World Health Organization; IMD: English Index of Multiple Deprivation; SCC: squamous cell carcinoma; HPV: human papil-
lomavirus.
*p-value for trend.
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Table 4. Details from mortality feedback forms returned 1-year after diagnosis.
Non-curative intent % (95% CIs) Curative intent % (95% CIs) p-value
Total deaths within 1 year of follow-up 109 – 482 – –
Total mortality forms 103 – 446 – –
Did this participant have a catastrophic bleed as a terminal event?  
 Yes 5 10.4 (4.3, 23.3) 22 9.5 (6.3, 14.0) 0.84
 No 43 89.6 (76.7, 95.7) 210 90.5 (86.0, 93.7)  
 Total 48 224  
Did this participant have an airway obstruction as a terminal event?  
 Yes 3 7.5 (2.3, 21.7) 12 6.1 (3.5, 10.4)  
 No 37 92.5 (78.3, 97.7) 186 93.9 (89.6, 96.5)  
 Total 40 192  
What was the place of death?  
 Home 40 40.8 (31.3, 51.0) 114 28.6 (24.4, 33.3) 0.097
 Hospice 23 23.5 (16.0, 33.0) 91 22.9 (19.0, 27.3)  
 Hospital 31 31.6 (23.1, 41.6) 182 45.7 (40.9, 50.7)  
 Care home 3 3.1 (1.0, 9.2) 8 2.0 (1.0, 4.0)  
 Other 1 1.0 (0.1, 7.1) 3 0.8 (0.2, 2.3)  
 Total 98 399  
CI: confidence interval.
people with head and neck cancer have a high preva-
lence of palliative care needs,38 complex symptoms,39 
and frequently require opioids and other medications 
to help with symptom control.40 Hence, developing and 
testing different models of care should be the focus of 
future studies. Within India, the first randomised con-
trolled study assessing the impact of early Specialist 
Palliative Care with stage IV head and neck cancer 
patients is currently being conducted (Muckaden MA, 
personal communication). Specialist Palliative Care is a 
limited resource. Hence, it is important to identify 
patients who most need specialist input and those who 
may benefit from a broader palliative and supportive 
care approach provided by the wider MDT. From our 
study, there appear to be two groups where screening 
for unmet needs and linkage into specialist palliative 
care services may be required shortly after diagnosis: 
those initially treated with ‘non-curative’ intent and a 
‘high risk’ subgroup of those initially treated with ‘cura-
tive’ intent, but who die within the first 12 months. 
Trying to prospectively identify this latter group remains 
a challenge.
To further understand the patient journeys, espe-
cially within the last year of life, undertaking research to 
explore the patient and family carer experience, symp-
tom burden and the level of healthcare utilisation would 
be beneficial. As part of a German multi-centre prospec-
tive study, the symptoms and needs of head and neck 
cancer patients at the point of incurability are being 
assessed using self-reported tools.41 An alternative 
method would be to undertake both longitudinal quan-
titative and qualitative research recruiting people with 
head and neck cancer and their families as they move 
from curative disease to palliative care. The addition of 
longitudinal qualitative methodology provides rich 
insights into an individual’s changing experience of their 
illness.42–44
Knowing more about the factors influencing treatment 
decision-making, especially when the chance of cure is 
small, would also be beneficial. Within the United 
Kingdom, a previous study suggested only 25% of head 
and neck cancer multi-disciplinary meetings (forums used 
to discuss the diagnosis and treatment planning) have 
direct presence from Specialist Palliative Care45 and it is 
unclear how much this situation has changed. A Dutch 
study examined the methods in which prognosis was 
communicated to people with head and neck cancer at 
various stages of their illness.46 Specific prognostic infor-
mation was often not included in these discussions and 
subsequent work is being conducted to help enhance 
shared decision-making.46
Finally, more detailed analysis of specific situations, 
using a ‘confidential enquiry’ approach, could help to bet-
ter understand the circumstances of deaths leading up to 
an acute catastrophic event and identify ways that these 
could be predicted, prevented or better managed.
Strengths and limitations of the study
This study has several strengths. First, it is a large, pro-
spective, national clinical cohort study which recruited 
people newly diagnosed with head and neck cancer. 
Second, those treated with ‘non-curative’ and ‘curative’ 
intent were recruited contemporaneously allowing com-
parisons between groups. Finally, the study collected pro-
spective data on mortality and place of death.
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The study had several weaknesses. First, the numbers 
within the ‘non-curative’ group were small. This limits 
the study’s power and is reflected by the wide CIs for 
some analyses. Second, possible issues including per-
ceived study burden and gatekeeping may have limited 
numbers of palliative participants who were recruited to 
the study. In addition, we do not have the reasons for 
non-participation, for example, lacks capacity and unwill-
ing to complete study questionnaires. It is possible that 
those treated with palliative intent and subsequently 
recruited are not representative of all people treated 
with palliative intent.47,48 In one study, 84/390 (21.5%) 
people with head and neck cancer were treated with pal-
liative intent following diagnosis.49 Third, the extent of 
missing data, especially for the place and mode of death, 
and the fact that data were recorded by the research 
team (rather than the clinical team) may limit their accu-
racy. More robust methods of eliciting this information 
would be useful within future research. Finally, the lim-
ited information available about the timing of referral 
and level of palliative care intervention leading up to 
death meant it was not possible to describe care path-
ways in detail.
Conclusion
In addition to those with incurable head and neck cancer, 
there is a small but significant ‘curative’ subgroup of peo-
ple who may have palliative needs shortly following diag-
nosis. Given the high mortality, risk of acute catastrophic 
events and frequent hospital death, clarifying the level 
and timing of palliative care services engagement would 
help provide assurance as to whether palliative care needs 
are being met. Effective models of palliative care that pro-
vide timely support, potentially including access to 
Specialist Palliative Care teams at the time of treatment 
planning, are important to support both people with head 
and neck cancer and their family carers.
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